Equities analysts expect that Krystal Biotech Inc (NASDAQ:KRYS) will post earnings of ($0.24) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Krystal Biotech’s earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.28). The firm is scheduled to issue its next earnings report on Monday, March 11th.

According to Zacks, analysts expect that Krystal Biotech will report full-year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($1.13) to ($0.88). For the next year, analysts anticipate that the company will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.54) to ($0.96). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Krystal Biotech.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 5th. The company reported ($0.26) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.26).

Several equities analysts recently weighed in on the stock. Cowen assumed coverage on shares of Krystal Biotech in a research report on Wednesday. They issued an “outperform” rating on the stock. Zacks Investment Research raised shares of Krystal Biotech from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Krystal Biotech in a research report on Monday, November 5th. William Blair reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Monday, November 5th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $35.00 price target on shares of Krystal Biotech in a research report on Monday, October 15th. Eight equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $33.20.

In other news, insider Krish S. Krishnan acquired 25,000 shares of the firm’s stock in a transaction on Thursday, October 18th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $500,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 45.80% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc increased its stake in Krystal Biotech by 13.1% in the 3rd quarter. Vanguard Group Inc now owns 173,478 shares of the company’s stock valued at $3,050,000 after buying an additional 20,100 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Krystal Biotech by 13.1% during the 3rd quarter. Vanguard Group Inc. now owns 173,478 shares of the company’s stock worth $3,050,000 after purchasing an additional 20,100 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Krystal Biotech during the 3rd quarter worth approximately $891,000. S Squared Technology LLC purchased a new stake in shares of Krystal Biotech during the 3rd quarter worth approximately $948,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Krystal Biotech by 69.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock worth $635,000 after purchasing an additional 14,755 shares during the last quarter. Hedge funds and other institutional investors own 18.83% of the company’s stock.

NASDAQ KRYS traded down $0.13 during trading hours on Friday, hitting $24.76. The company’s stock had a trading volume of 48,411 shares, compared to its average volume of 47,145. Krystal Biotech has a 52 week low of $8.03 and a 52 week high of $28.75. The stock has a market cap of $359.14 million, a price-to-earnings ratio of -16.73 and a beta of -0.66.

About Krystal Biotech

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

Further Reading: What are the benefits of buying treasury bonds?

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.